Safinamide Mesylate

CHEMBL48582 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
398.5 g/mol
LogP
Phase
4

A mesylate salt form of safinamide with the same therapeutic properties. Taken as an add-on to levodopa therapy, this medication helps smooth out the motor fluctuations that Parkinson's patients experience as their levodopa dose wears off.

น้ำหนักโมเลกุล

398.5000 g/mol

TPSA

127.00 Ų

ด้านการรักษา

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CS(=O)(=O)O.C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O

InChI

InChI=1S/C17H19FN2O2.CH4O3S/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14;1-5(2,3)4/h2-9,12,20H,10-11H2,1H3,(H2,19,21);1H3,(H,2,3,4)/t12-;/m0./s1

Molecular Formula

C18H23FN2O5S

HBD / HBA

3 / 7

พันธะที่หมุนได้

7

อะตอมหนัก

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A mesylate salt form of safinamide with the same therapeutic properties. Taken as an add-on to levodopa therapy, this medication helps smooth out the motor fluctuations that Parkinson's patients experience as their levodopa dose wears off.

Yes, Safinamide Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL48582. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3038502. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.